GRAF gene expression in patients with acute and chronic myeloid leukaemia: impact on the prognosis

Objective We aimed to assess the expression level of GRAF gene in patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) and to clarify its prognosticsignificance on the clinical outcome. Background GTPase regulator associated with focal adhesion kinase (GRAF) is a newly ident...

Full description

Saved in:
Bibliographic Details
Published in:The Egyptian journal of haematology : the official journal of the Egyptian Society of Haematology 2020-07, Vol.45 (3), p.121-128
Main Authors: Tolbaa, Fetnat, Diab, Safia, El-Ghanam, Doaa, Mahmoud, Ghada, El-Shabrawy, Deena
Format: Article
Language:English
Subjects:
Ethylenediaminetetraacetic acid
Gene expression
Genes
Genetic aspects
Genetic research
Protein binding
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective We aimed to assess the expression level of GRAF gene in patients with acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) and to clarify its prognosticsignificance on the clinical outcome. Background GTPase regulator associated with focal adhesion kinase (GRAF) is a newly identified protein specifically binding to focal adhesion kinase and negatively regulates the small GTP-binding protein RhoA, which is well known for its growth-promoting effect in RAS-mediated malignant transformation. GRAF is recognized as a tumor suppressor gene that binds to focal adhesion kinase. Methods In this study, we investigated the expression of the GRAF transcript by realtime quantitative PCR in 37 AML patients, 35 CML patients and 15 healthy and sex-matched controls, and to clarify its prognostic significance on the clinical outcome. Results We found that the GRAF expression is low in patients with AML and CML. A high GRAF expression is a favorable prognostic marker in patients with AML and CML. In AML, high GRAF transcript. Conclusion High GRAF expression is a favorable prognostic marker in AML patients and a protective factor against CML progression.
ISSN:1110-1067
2090-9268
DOI:10.4103/ejh.ejh_31_17